Summary of Significant Accounting Policies - Schedule of Percentage of Revenues and Accounts Receivables from Customers (Details) - Customer Concentration Risk	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
VA MVP | Revenues
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	76.00%	54.00%	76.00%	56.00%
VA MVP | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			17.00%		19.00%
Pfizer Inc. | Revenues
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	10.00%	23.00%		20.00%
Pfizer Inc. | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			44.00%		23.00%
Customer D | Revenues
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		12.00%
Indivumed GmbH | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage					30.00%
Customer H | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			14.00%